<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16-pharmaceuticals-13-00233">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bourikas</surname>
    <given-names>L.A.</given-names>
   </name>
   <name>
    <surname>Kolios</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Valatas</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Notas</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Drygiannakis</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Pelagiadis</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Manousou</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Klironomos</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>A Mouzas</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Kouroumalis</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-Î²1 secretion and enhances the anti-proliferative effect of 5-fluorouracil</article-title>
  <source>Br. J. Pharmacol.</source>
  <year>2009</year>
  <volume>157</volume>
  <fpage>362</fpage>
  <lpage>370</lpage>
  <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00161.x</pub-id>
  <?supplied-pmid 19371339?>
  <pub-id pub-id-type="pmid">19371339</pub-id>
 </element-citation>
</ref>
